Thorac Cardiovasc Surg 2012; 60 - PP13
DOI: 10.1055/s-0031-1297660

The mosaic bioprosthesis in the aortic position: 17 years' results

B Gansera 1, F Botzenhardt 1, K Brandl 1, A Hapfelmeier 2, W Eichinger 1
  • 1Städt. KH München Bogenhausen, Klinik f. Herzchirurgie, München, Germany
  • 2Technische Universität München, Institut für medizinische Statistik und Epidemiologie, München, Germany

Objectives: The mosaic bioprosthesis, a stented porcine aortic valve combines glutaraldehyd fixation with zero-pressure, root-pressure techniques and antiminerlization treatment with amino-oleic acid for improved hemodynamics and tissue durability. Worldwide, the first device has been implanted at author's institution in September1993. Aim of the present study was to collect long-term data of the prosthesis.

Methods: A total of 272 patients (124 males, 148 females) underwent isolated aortic valve replacement with the Mosaic bioprosthesis between 9/1993 and 8/2007. Age at implant was median 76.8 years (range 31.3–90.7). Median follow up was 12.0 years

(0–17.2 years); follow up was complete for 82%.

Results: Early mortality (30-day) was 4.4%. Survival rates were: 68.6±0.03% at 5, 36.4±0.03% at 10, 17.1±0.03% at 15 and 10.7±0.04% at 17 years.11 late deaths (4.9%) were cardiac related. Freedom from advers events at a median follow up of 12 years was 88.8% for thromboembolic events, 100% for hemorrhage, 97.8% for reoperation/explant.2 redoes were due to structural valve deterioration, 2 for non-structural dysfunction, 1 for endocarditis.

Conclusions: Performance and late outcome of the Mosaic bioprosthesis was highly satisfactory during 17 years after clinical introduction.